Irreversible protein kinase inhibitors.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Pharmacology

Background:

• Small molecule irreversible inhibitors represent an emerging strategy for targeting kinases in cancer drug discovery.
• These inhibitors covalently bind to a nucleophilic cysteine residue near the ATP binding pocket, typically via a Michael reaction with an α,β unsaturated carbonyl.
• This irreversible binding mechanism blocks ATP binding, rendering the kinase inactive.

Purpose of the Study:

• To review examples of irreversible kinase inhibitors, focusing on their chemical structures, structure-activity relationships (SAR), and biological activities.
• To highlight the advantages and potential of irreversible kinase inhibition in cancer therapy.

Main Methods:

• Review of existing literature on irreversible kinase inhibitors.
• Analysis of chemical structures, including the use of acrylamide or substituted acrylamide moieties as Michael acceptors.
• Evaluation of SAR and biological activities reported for these inhibitors.

Main Results:

• Irreversible inhibitors demonstrate high selectivity by targeting specific cysteine residues, which are present in a limited number of kinases.
• Covalent bond formation overcomes competition from high endogenous ATP concentrations.
• These inhibitors offer a longer duration of action compared to conventional inhibitors and have the potential to overcome acquired resistance mutations.

Conclusions:

• Irreversible kinase inhibitors present significant advantages, including enhanced selectivity, prolonged action, and the ability to circumvent resistance mechanisms.
• The development of these compounds holds great potential for advancing cancer therapy.
• Further exploration of irreversible inhibitors could lead to broader applications in drug discovery.